Milestone Pharmaceuticals Inc
milestonepharma.comWhat Do They Do?
Sells CARDAMYST, a prescription nasal spray for people with sudden episodes of rapid heartbeat, and develops etripamil for other heart rhythm conditions.
10-K for FY2025, filed Mar 20, 2026We are a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Our approved…View ↗
On December 12, 2025, we announced that the FDA approved our first commercial product, CARDAMYST (etripamil) nasal spray, a prescription…View ↗
We designed the molecule of etripamil, and we are commercializing and further developing the drug, a novel, potent, and rapid-onset calcium…View ↗
Who Are Their Customers?
In the United States, the company promotes CARDAMYST to cardiologists, electrophysiologists and some primary-care physicians, and distributes it through wholesalers to retail pharmacies after prescriptions are received.
10-K for FY2025, filed Mar 20, 2026
Do Revenues Turn Into Profits?
No. It lost $63.1M in .
10-K for FY2025, filed Mar 20, 2026
−$62.1MView ↗
10-K for FY2025, filed Mar 20, 2026
−$63.1MView ↗
10-K for FY2025, filed Mar 20, 2026
−$49.3MView ↗
How Are They Changing?
-
Sep 3, 2026
China approves etripamil nasal spray for PSVT in adults
Everest Medicines will lead commercialization in Greater China; approval triggers a $2.0 million milestone payment.
Sources
8-K, filed Sep 3, 2026
The NMPA decision marks the first regulatory approval of etripamil outside the United States and triggers a $2.0 million milestone payment…View ↗
From development to sales
The older report described etripamil as a lead product candidate in development; the latest report describes CARDAMYST as approved and being commercialized in the United States, while development continues for other heart rhythm conditions.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Mar 20, 2026We are a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Our lead…View ↗
Who Do They Compete With?
Competes with InCarda Therapeutics and Acesion Pharma
10-K for FY2025, filed Mar 20, 2026For AFib, there are a number of marketed generic antiarrhythmic drugs that are used for chronic and/or acute rate control, such as…View ↗
Loading...
